Diseases / Sepsis
Sepsis
DiseaseSepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. Without early recognition and treatment, it can progress to septic shock, multi-organ failure, and death.
- Trials
- 2265
- Recruiting
- 232
- Completed
- 1150
- With results
- 145
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Suspended | Unknown | Approved for marketing | No longer available | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | 2 | — | — | — | 2 | — | — | — | — | — | — | 4 |
| Phase 1 | 3 | 2 | — | — | 46 | 7 | 2 | — | 1 | — | — | 61 |
| Phase 1/2 | 2 | 3 | 1 | 1 | 19 | 3 | 2 | — | 5 | — | — | 36 |
| Phase 2 | 13 | 5 | — | 2 | 76 | 11 | 11 | 1 | 24 | — | — | 143 |
| Phase 2/3 | 2 | — | — | 1 | 21 | 7 | 1 | 1 | 13 | — | — | 46 |
| Phase 3 | 12 | 7 | — | 1 | 90 | 17 | 6 | 2 | 25 | — | — | 160 |
| Phase 4 | 18 | 11 | 1 | 4 | 69 | 12 | 4 | — | 23 | — | — | 142 |
| Not applicable | 56 | 42 | 2 | 8 | 293 | 30 | 21 | 1 | 97 | — | — | 550 |
| Unknown | 124 | 78 | 15 | 27 | 534 | 28 | 25 | 3 | 286 | 1 | 2 | 1123 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Sepsis | 4 | 61 | 36 | 143 | 46 | 160 | 142 | 550 | 1123 | 2265 |
| Shock, Septic | 1 | 14 | 13 | 52 | 16 | 49 | 40 | 128 | 225 | 538 |
| Critical Illness | — | 5 | 4 | 7 | 3 | 7 | 6 | 45 | 85 | 162 |
| Infections | — | 1 | 1 | 11 | 2 | 13 | 11 | 29 | 91 | 159 |
| Acute Kidney Injury | — | — | 4 | 6 | 1 | 5 | 8 | 23 | 52 | 99 |
| Systemic Inflammatory Response Syndrome | — | 1 | 2 | 6 | 2 | 5 | 4 | 15 | 51 | 86 |
| Bacteremia | — | 1 | — | 4 | — | 8 | 8 | 17 | 41 | 79 |
| Shock | — | 2 | 1 | 7 | 2 | 7 | 4 | 18 | 37 | 78 |
| Pneumonia | — | 1 | 1 | 2 | 1 | 10 | — | 15 | 45 | 75 |
| Respiratory Distress Syndrome | — | 3 | 2 | 10 | — | 5 | — | 15 | 28 | 63 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | Assistance Publique - Hôpitaux de Paris | 31 | 5 |
| 2 | Ain Shams University | 27 | 3 |
| 3 | Assiut University | 23 | 1 |
| 4 | National Taiwan University Hospital | 21 | 1 |
| 5 | Chinese PLA General Hospital | 20 | 0 |
| 6 | Southeast University, China | 20 | 2 |
| 7 | Tanta University | 19 | 1 |
| 8 | Radboud University Medical Center | 16 | 5 |
| 9 | Mayo Clinic | 15 | 0 |
| 10 | University of Florida | 15 | 0 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Blood Specimen Collection | 51 |
| 2 | Saline Solution | 43 |
| 3 | Sodium Chloride | 34 |
| 4 | Ascorbic Acid | 33 |
| 5 | Hydrocortisone | 26 |
| 6 | Standard of Care | 26 |
| 7 | Meropenem | 24 |
| 8 | Thiamine | 19 |
| 9 | Norepinephrine | 18 |
| 10 | Dexmedetomidine | 14 |
Evidence
- Results reported
- 12.6%145 of 1150 completed
- Published
- 17.3%199 of 1150 completed
- Primary endpoint met
- 25%17 of 68 analyses
- Median months to report
- 14
Documents disclosed
Trial profile
- Median enrollment
- 116
- Median duration
- 24months
- Countries
- 114
- Study sites
- 6990
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 110
- Phase 1
- 30
- Phase 1/2
- 40
- Phase 2
- 69
- Phase 2/3
- 108
- Phase 3
- 238
- Phase 4
- 100
- Not applicable
- 100
- Unknown
- 150
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | Paris | France | 69 |
| 2 | Boston | United States | 65 |
| 3 | Beijing | China | 53 |
| 4 | Houston | United States | 50 |
| 5 | London | United Kingdom | 49 |
| 6 | Shanghai | China | 48 |
| 7 | Brussels | Belgium | 46 |
| 8 | Barcelona | Spain | 43 |
| 9 | Detroit | United States | 43 |
| 10 | Nanjing | China | 42 |
Terminations
- Terminated
- 115
- Withdrawn
- 72
- Suspended
- 8
- Stopped for recruitment
- 2.1%48 of 2265 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT04110912 Withdrawn | Withdrawn | No longer proceeding with application | 2040-12-31 |
| NCT07492875 Withdrawn | Withdrawn | New protocol developed | 2029-12-31 |
| NCT04742764 Suspended | Suspended | The human resources required to start enrollment were not available anymore. | 2027-10-31 |
| NCT03278730 Suspended | Suspended | Lack of resources to start | 2027-02-28 |
| NCT07492888 Withdrawn | Withdrawn | New protocol developed | 2027-01-15 |
| NCT06668870 Withdrawn | Withdrawn | protocol changes were made and study no longer a clinical trial | 2026-10-31 |
| NCT06627842 Suspended | Suspended | Temporary suspended. Wait for IRB approval (inclusion duration modified) | 2026-10-01 |
| NCT06885528 Terminated | Terminated | The study was discontinued due to a change in the company's strategic priorities for its hematology platform and was not related to concerns regarding the clinical performance, validity, or safety of MDW. | 2026-07-08 |
| NCT06217939 Terminated | Terminated | The study was terminated early on December 25, 2025, following the Data and Safety Monitoring Board (DSMB) recommendation due to preliminary evidence of futility. | 2026-04-25 |
| NCT05148117 Withdrawn | Withdrawn | Could not get through IRB submission and co-investigators with needed skillsets for study departed organization | 2026-01-14 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above: